Tempero Bio has raised $70m in Series B financing to advance its lead candidate TMP-301 through two clinical trials for ...
We can also explore the development of specific thresholds based on patients’ circumstances, such as pre-existing conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback